Syros Pharmaceuticals to Present on its Two Lead Programs, SY-1425 and SY-1365, at 21st Congress of the European Hematology Association

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals today announced that preclinical data on its lead program, SY-1425, in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be highlighted in an oral presentation at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12 in Copenhagen, Denmark. The Company will also present new preclinical data on its first-in-class selective cyclin-dependent kina
Source: BusinessWire-Primary

Syros Pharmaceuticals to Present on its Two Lead Programs, SY-1425 and SY-1365, at 21st Congress of the European Hematology Association